Furthermore, the sensitivity analysis that was performed after the exclusion of the CREDENCE data revealed a significant reduction in the risk of cardiovascular events compared with placebo in patients taking GLP-1 RAs with obesity (Table 3). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.